Honeywell's Technology Chosen By Phu My Plastics Production
Zacks Investment Research | Mar 13, 2019 12:45AM ET
Honeywell International Inc. (NYSE:HON) recently announced that its business unit, Honeywell UOP, has been selected by Phu My Plastics Production JSC to provide its state-of-the-art UOP technology in Vietnam. Notably, Phu My Plastics Production will be using Honeywell UOP's C3 Oleflex technology for the production of polymer-grade propylene at its facility. This will enable the plant to cater to the increasing requirement of plastics in Vietnam as well as other countries in Southeast Asia.
Honeywell UOP is a division of Honeywell's Performance Materials and Technologies strategic business group, which also comprises Honeywell Process Solutions. Per the deal, Honeywell UOP will be responsible for providing technology licenses for the Oleflex process. In sync with the deal, the company will also provide proprietary and non-proprietary equipment, process design package, proprietary catalysts, adsorbents as well as on-site operator training, among others.
Notably, the company’s C3 Oleflex technology helps in converting propane to propylene with the help of catalytic dehydrogenation. With recyclable and low emissions features, its platinum-alumina-based catalyst system ensures minimization of harmful effect on the environment. As a matter of fact, C3 Oleflex technology’s independent reaction and regeneration sections will allow Phu My Plastics Production to boost operational flexibility, apart from ensuring steady-state of operations and improved on-stream reliability.
Our Take
Honeywell believes that strength in licensing and engineering sales is likely to keep driving revenues of its Performance Materials and Technology business. Also, solid demand for its commercial fire and productivity products will boost the company’s Safety and Productivity Solutions’ revenues in the quarters ahead. It currently anticipates generating organic sales growth in the range of 2-5% in 2019.
Over the past year, this Zacks Rank #3 (Hold) company's shares have gained 2.1% against 6.7% decline recorded by the industry .
Moreover, the company is progressing well with its portfolio transformation strategy, having declared spin-off dividends of shares of Resideo, and completing the divestment of Garrett Motion Inc. In addition, Honeywell completed the acquisition of the German company Transnorm (November 2018). As a matter of fact, these initiatives are likely to help it concentrate on high-growth industrial businesses and thus boost sales growth.
Get The News You Want
However, Honeywell is currently dealing with rising costs of sales. Notably, in 2018, the company's cost of sales increased 5.3% year over year. Gross margin for the year was down 140 basis points. Also, high research and development costs could also be a drag on the Aerospace segment's profitability.
Key Picks
Some better-ranked stocks in the same space are Carlisle Companies Inc. (NYSE:CSL) , Macquarie Infrastructure Co. (NYSE:MIC) and Federal Signal Corp. (NYSE:FSS) . While Carlisle sports a Zacks Rank #1 (Strong Buy), Macquarie Infrastructure and Federal Signal carry a Zacks Rank #2 (Buy). You can see .
Carlisle pulled off average positive earnings surprise of 15.00% in the trailing four quarters.
Macquarie Infrastructure delivered average earnings surprise of 0.51% in the trailing four quarters.
Federal Signal delivered average positive earnings surprise of 21.57% in the trailing four quarters.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.